Standard BioTools Inc. Common Stock (LAB)

Price$1.15

Value ScoreB

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-26.09%

Price vs S&P 500 (4W)17.37%

VGM Score45.63

Market Capitalization$448.92M

All Metrics

Book Value / Share (Quarterly)$1.44

P/TBV (Annual)1.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-4.48%

Cash Flow / Share (Quarterly)$-0.24

Price vs S&P 500 (YTD)-21.09%

Gross Margin (TTM)49.62%

Net Profit Margin (TTM)90.67%

EPS (TTM)$0.20

10-Day Avg Trading Volume2.19M

EPS Excl Extra (TTM)$0.20

Revenue Growth (5Y)-9.18%

EPS (Annual)$-0.20

ROI (Annual)-29.41%

Gross Margin (Annual)49.86%

Net Profit Margin (5Y Avg)-95.42%

Cash / Share (Quarterly)$1.17

P/E Basic Excl Extra (TTM)5.74x

Revenue Growth QoQ (YoY)-48.17%

ROA (Last FY)-22.69%

Revenue Growth TTM (YoY)-49.17%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-51.72%

Operating Margin (TTM)-111.04%

Cash Flow / Share (Annual)$-0.40

P/B Ratio0.80x

P/B Ratio (Quarterly)0.64x

Net Income / Employee (Annual)$-194,500

EV / Revenue (TTM)2.13x

Net Interest Coverage (TTM)-15.25x

ROA (TTM)13.58%

EPS Incl Extra (Annual)$-0.20

Current Ratio (Annual)5.70x

Quick Ratio (Quarterly)11.77x

3-Month Avg Trading Volume2.22M

52-Week Price Return8.49%

P/E Incl Extra (TTM)5.74x

Revenue / Employee (TTM)$224,000

Tangible BV / Share (Quarterly)$1.13

P/S Ratio (Annual)5.26x

Asset Turnover (Annual)0.28x

52-Week High$1.72

Operating Margin (5Y Avg)-86.05%

EPS Excl Extra (Annual)$-0.20

CapEx CAGR (5Y)-8.18%

26-Week Price Return-10.16%

Quick Ratio (Annual)4.94x

13-Week Price Return-1.71%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.36x

Enterprise Value$183.45M

Revenue / Share Growth (5Y)-34.94%

Asset Turnover (TTM)0.15x

Book Value / Share Growth (5Y)29.38%

Revenue / Employee (Annual)$221,600

Inventory Turnover (Annual)1.49x

Pretax Margin (Annual)-113.33%

Cash / Share (Annual)$0.78

3-Month Return Std Dev50.05%

Gross Margin (5Y Avg)42.81%

Net Income / Employee (TTM)$203,100

ROE (Last FY)-29.42%

Net Interest Coverage (Annual)-15.25x

EPS Basic Excl Extra (Annual)$-0.20

Receivables Turnover (TTM)3.41x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.20

Receivables Turnover (Annual)5.75x

ROI (TTM)17.28%

P/S Ratio (TTM)5.20x

Pretax Margin (5Y Avg)-96.15%

Revenue / Share (Annual)$0.22

Tangible BV / Share (Annual)$1.17

Price vs S&P 500 (52W)-19.72%

P/E Ratio (TTM)5.74x

Year-to-Date Return-10.16%

5-Day Price Return11.65%

EPS Normalized (Annual)$-0.20

ROA (5Y Avg)-26.47%

Net Profit Margin (Annual)-87.77%

Month-to-Date Return23.66%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-0.26

Operating Margin (Annual)-129.20%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-38.00%

P/E Excl Extra (TTM)5.74x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.20

P/TBV (Quarterly)0.96x

P/B Ratio (Annual)1.38x

Inventory Turnover (TTM)1.43x

Pretax Margin (TTM)-101.82%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)-11.46%

Beta1.43x

Revenue / Share (TTM)$0.22

ROE (TTM)17.29%

52-Week Low$0.87

vGradeB

gGradeF

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.33est. -0.06

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.86

Industry Peers — Lab Analytical Instruments(24)

Symbol	Value Score	Growth Score	Momentum Score	Price
LABStandard BioTools Inc. Common Stock	B	F	B	$1.15
AAgilent Technologies Inc.	C	C	B	$135.98
WATWaters Corp	D	C	B	$378.16
ILMNIllumina Inc	D	D	A	$164.40
MTDMettler-Toledo International	D	C	C	$1183.57
RVTYRevvity, Inc.	C	D	B	$100.52
BRKRBruker Corporation	D	D	A	$58.44
BIOBio-Rad Laboratories, Inc.Class A	C	F	B	$305.46
BIO.BBio-Rad Laboratories, Inc. Class B	C	F	B	$304.15
AVTRAvantor, Inc.	B	D	C	$9.19
TXG10x Genomics, Inc. Class A Common Stock	D	C	A	$29.59

About

Standard BioTools develops and manufactures advanced analytical instruments for biomedical research, primarily using mass cytometry and microfluidics technologies to accelerate drug discovery. The company operates two core segments—Proteomics and Genomics—with Proteomics representing the largest revenue contributor. Its solutions enable researchers to gain deeper insights into health and disease mechanisms, supporting faster therapeutic development. The company generates the majority of its revenue from the Americas.